Currently in vitro fertilisation (IVF) patients suffer more than double the failure rates of couples who conceive naturally, as IVF techniques are unable to gauge immunogenetic compatibility, a factor that is otherwise taken into account subconsciously via highly evolved chemical signalling pathways. For fertility clinics, whilst success rates are the primary differentiator, the difference between best and worst performing clinics is only 15%. As a result, competition for technologies that can increase success rates is fierce. For customers, each failed cycle costs approximately £5,000, as well as severe emotional costs. This market is growing at 11% CAGR as fertility declines and maternal age increases.
Immune Compass are developing a genetic matching technology for fertility treatments. They apply insights from complexity science and artificial intelligence research to this rapidly growing field to build the world’s first immunogenetic compatibility tool. They have secured a partnership and pilot with one of the largest fertility services companies in Europe, with 15 clinics in 4 countries, and are currently proving their technology on a donated dataset. Beyond their work with clinics, the team have set their sights on an at-home fertility test, which could help to diagnose the cause of failure to conceive.